<DOC>
	<DOCNO>NCT00749411</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability repeat dose combination inhale GSK233705 GW642444 administer once-daily subject COPD .</brief_summary>
	<brief_title>Safety Tolerability Repeat Dosing GSK233705/GW642444 COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>male female 40 80 year age ( inclusive ) COPD diagnosis Current previous smoker cigarette smoke history least 10 pack Postalbuterol FEV1/FVC 0.70 less Postalbuterol FEV1 35 % 80 % ( inclusive ) Pregnant lactate female current diagnosis asthma respiratory disorder COPD clinically significant cardiovascular , neurological , psychiatric , renal , immunological , endocrine , hematological abnormality uncontrolled clinically significant sleep apnea previous lung resection surgery clinically significant abnormality confirm chest xray related COPD hospitalization COPD within 3 month screen use antibiotic low respiratory tract infection within 6 month screen abnormal clinically significant 12lead ECG finding current malignancy remission le 5 year medical condition would contraindicate use anticholinergic positive hepatitis B C test history alcohol drug abuse unable withhold albuterol 6 hour use long term oxygen therapy condition would limit validity inform consent use GW642444 GSK233705 previous study use investigation drug 30 day screen use inhaled corticosteroid ( ICS ) dose great 1000mcg fluticasone propionate equivalent hypersensitivity betaagonists concurrent use longacting betaagonists ( LABA ) longacting muscaring antagonist , LABA/ICS combination product , cytochrome p450 inhibitor , oral depot corticosteroid , theophylline , oral beta agonist , oral leukotrine modulators , inhale short act anticholinergic .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>long-acting beta agonist</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>long act muscarinic antagonist</keyword>
</DOC>